New Hampshire lawmakers are currently weighing a decision that could fundamentally alter the state’s approach to substance control.
As the legislature revisits the status of kratom, proposals have moved beyond simple oversight, with some advocates pushing to classify the entire plant as a Schedule I controlled substance. This move would place botanical kratom in the same legal category as heroin, a step that carries profound implications for researchers, consumers, and public health policy.
The core of this debate centers on a disconnect between traditional botanical use and the modern, high-potency market. While the kratom plant, Mitragyna speciosa, has been used for centuries in Southeast Asia, the current American marketplace is flooded with products that bear little resemblance to the dried leaves of the past.
Today, shelves are stocked with semi- and fully synthetic compounds, highly concentrated 7-OH products, and chemically modified derivatives that pose legitimate safety risks.
The stakes for consumers are high. Many individuals currently use botanical kratom preparations to manage pain or address conditions where traditional treatments have failed. By enforcing a blanket prohibition, the state risks pushing these users toward less regulated, illicit alternatives or back to conventional opioids. As an addiction psychiatrist, the author of a recent analysis notes the complexity of the current situation:
“The kratom plant has been used for centuries in Southeast Asia without much concern, but the products we have here created legitimate public health concerns. Recognizing a problem and choosing the appropriate solution are two separate entities.”
Distinguishing Botanical Leaves from Synthetic Chemicals
A primary challenge for regulators is the sheer variability of products labeled as “kratom.” A 2026 analysis from the Centers for Disease Control and Prevention identified a 1,200% increase in kratom-related exposure reports between 2015 and 2025. Crucially, however, the investigators could not reliably distinguish between traditional botanical kratom and the synthetic, chemically modified derivatives that now dominate the market. This ambiguity makes it difficult to attribute these health outcomes to the plant itself.
A 2026 observational study examining poison center-reported kratom exposures from 2010 through 2023 found that while states with full bans reported lower exposure rates, there were no statistically significant differences among states with consumer protection laws, local restrictions and states with unrestricted access. The data suggests that prohibition is not a guaranteed remedy for harm, as it fails to account for the nuances of how these products are actually consumed and regulated.
Lessons from the Rhode Island Model
New Hampshire does not necessarily have to choose between a completely unregulated market and a total ban. Other states are experimenting with tiered regulatory frameworks that prioritize transparency and safety. Rhode Island, for instance, recently moved away from an outright ban to implement the Rhode Island Kratom Act. This law shifts oversight to the Department of Health, which now licenses manufacturers and retailers while enforcing strict labeling requirements.
This framework includes several specific safeguards that could serve as a template for New Hampshire:
- Mandatory age verification for all buyers, restricted to those 21 and older.
- Independent, third-party laboratory testing to identify contaminants and synthetic adulterants.
- Clear, transparent labeling detailing composition per serving and container.
- Strict prohibitions on semi- and fully synthetic products that mimic opioid receptor activity.
- A 15% wholesale tax to fund ongoing regulatory surveillance and enforcement.
Earlier this year, Senate Bill 557 attempted to address these synthetic products in New Hampshire, but the proposal failed to secure the necessary consensus.
As the conversation continues, the challenge remains to develop a policy that holds manufacturers accountable without criminalizing a botanical substance that many consumers use for self-management. Whether the state will opt for a evidence-based regulatory framework or move toward a more restrictive, absolute prohibition remains an open question.